NT_1170x120_1-11-18

Peter Guenter

Sanofi launches Soliqua 100/33 insulin pen

Sanofi launches Soliqua 100/33 insulin pen

PARIS — Sanofi has released Soliqua 100/33, an insulin injection for type 2 diabetes, to U.S. pharmacies. The company said Wednesday that Soliqua 100/33 (insulin glargine 100 units/ml and lixisenatide 33 mcg/ml) comes in a single, prefilled SoloStar pen with a dosage range of 15 to 60 units and two starting doses to support patients’

Sanofi cleared by FDA to market Adlyxin

Sanofi cleared by FDA to market Adlyxin

PARIS — Sanofi has gained Food and Drug Administration approval for Adlyxin (lixisenatide), a medication for type 2 diabetes. A once-daily mealtime GLP-1 receptor agonist injection, Adlyxin is indicated as an adjunct to diet and exercise for improving blood glucose control in the treatment of adults with type 2 diabetes.Sanofi said this week that Adlyxin